PAH patients with a poor response to DCA carried functional inactivating variants of genes encoding sirtuin-3 (SIRT3) and uncoupling protein 2 (UCP2) [78], suggesting that the presence of physiologically functioning SIRT3 and UCP2 is crucial for the manifestation of DCA benefits. Here, UCP2 is linked to pulmonary arterial hypertension.